Annual Total Liabilities
$1.70 B
+$50.19 M+3.04%
December 31, 2024
Summary
- As of February 23, 2025, HALO annual total liabilities is $1.70 billion, with the most recent change of +$50.19 million (+3.04%) on December 31, 2024.
- During the last 3 years, HALO annual total liabilities has risen by +$792.18 million (+87.29%).
- HALO annual total liabilities is now at all-time high.
Performance
HALO Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$1.70 B
+$34.33 M+2.06%
December 31, 2024
Summary
- As of February 23, 2025, HALO quarterly total liabilities is $1.70 billion, with the most recent change of +$34.33 million (+2.06%) on December 31, 2024.
- Over the past year, HALO quarterly total liabilities has stayed the same.
- HALO quarterly total liabilities is now -3.84% below its all-time high of $1.77 billion, reached on September 30, 2022.
Performance
HALO Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
HALO Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +3.0% | 0.0% |
| 3 y3 years | +87.3% | +3.4% |
| 5 y5 years | +258.5% | +3.4% |
HALO Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +87.3% | -3.8% | +88.4% |
| 5 y | 5-year | at high | +296.3% | -3.8% | +303.3% |
| alltime | all time | at high | >+9999.0% | -3.8% | >+9999.0% |
Halozyme Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $1.70 B(+3.0%) | $1.70 B(+2.1%) |
| Sep 2024 | - | $1.67 B(-0.9%) |
| Jun 2024 | - | $1.68 B(+1.0%) |
| Mar 2024 | - | $1.66 B(+0.9%) |
| Dec 2023 | $1.65 B(-1.3%) | $1.65 B(+0.4%) |
| Sep 2023 | - | $1.64 B(-1.0%) |
| Jun 2023 | - | $1.66 B(+1.6%) |
| Mar 2023 | - | $1.63 B(-2.3%) |
| Dec 2022 | $1.67 B(+84.2%) | $1.67 B(-5.4%) |
| Sep 2022 | - | $1.77 B(+18.8%) |
| Jun 2022 | - | $1.49 B(+65.0%) |
| Mar 2022 | - | $901.99 M(-0.6%) |
| Dec 2021 | $907.48 M(+111.6%) | $907.48 M(+0.4%) |
| Sep 2021 | - | $903.75 M(-0.3%) |
| Jun 2021 | - | $906.12 M(+0.8%) |
| Mar 2021 | - | $898.99 M(+109.6%) |
| Dec 2020 | $428.88 M(-9.5%) | $428.88 M(+0.9%) |
| Sep 2020 | - | $425.04 M(+0.9%) |
| Jun 2020 | - | $421.42 M(-3.0%) |
| Mar 2020 | - | $434.31 M(-8.4%) |
| Dec 2019 | $474.11 M(+147.8%) | $474.11 M(+279.3%) |
| Sep 2019 | - | $125.00 M(-20.8%) |
| Jun 2019 | - | $157.78 M(-6.7%) |
| Mar 2019 | - | $169.06 M(-11.7%) |
| Dec 2018 | $191.36 M(-38.6%) | $191.36 M(-6.5%) |
| Sep 2018 | - | $204.77 M(-6.9%) |
| Jun 2018 | - | $219.83 M(-4.6%) |
| Mar 2018 | - | $230.41 M(-26.1%) |
| Dec 2017 | $311.58 M(+6.0%) | $311.58 M(+9.4%) |
| Sep 2017 | - | $284.76 M(-0.6%) |
| Jun 2017 | - | $286.62 M(+0.5%) |
| Mar 2017 | - | $285.27 M(-3.0%) |
| Dec 2016 | $294.00 M(+111.8%) | $294.00 M(-0.2%) |
| Sep 2016 | - | $294.49 M(+2.9%) |
| Jun 2016 | - | $286.21 M(+2.4%) |
| Mar 2016 | - | $279.62 M(+101.5%) |
| Dec 2015 | $138.79 M(+11.4%) | $138.79 M(+9.3%) |
| Sep 2015 | - | $126.94 M(+2.5%) |
| Jun 2015 | - | $123.82 M(+1.8%) |
| Mar 2015 | - | $121.58 M(-2.4%) |
| Dec 2014 | $124.63 M(+2.3%) | $124.63 M(-0.0%) |
| Sep 2014 | - | $124.69 M(-1.6%) |
| Jun 2014 | - | $126.75 M(-3.2%) |
| Mar 2014 | - | $130.94 M(+7.5%) |
| Dec 2013 | $121.78 M | $121.78 M(+7.2%) |
| Sep 2013 | - | $113.63 M(+18.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2013 | - | $96.24 M(+13.0%) |
| Mar 2013 | - | $85.19 M(-0.8%) |
| Dec 2012 | $85.87 M(+56.5%) | $85.87 M(+51.2%) |
| Sep 2012 | - | $56.79 M(+8.1%) |
| Jun 2012 | - | $52.51 M(-2.1%) |
| Mar 2012 | - | $53.66 M(-2.2%) |
| Dec 2011 | $54.86 M(-22.7%) | $54.86 M(+7.2%) |
| Sep 2011 | - | $51.19 M(-26.3%) |
| Jun 2011 | - | $69.46 M(+3.0%) |
| Mar 2011 | - | $67.42 M(-5.0%) |
| Dec 2010 | $70.99 M(+1.1%) | $70.99 M(+8.6%) |
| Sep 2010 | - | $65.39 M(-0.3%) |
| Jun 2010 | - | $65.60 M(-4.0%) |
| Mar 2010 | - | $68.36 M(-2.7%) |
| Dec 2009 | $70.25 M(+14.8%) | $70.25 M(+1.1%) |
| Sep 2009 | - | $69.51 M(-0.5%) |
| Jun 2009 | - | $69.86 M(+7.5%) |
| Mar 2009 | - | $65.00 M(+6.2%) |
| Dec 2008 | $61.18 M(+33.9%) | $61.18 M(+22.7%) |
| Sep 2008 | - | $49.87 M(+2.0%) |
| Jun 2008 | - | $48.90 M(-1.4%) |
| Mar 2008 | - | $49.60 M(+8.6%) |
| Dec 2007 | $45.69 M(+98.6%) | $45.69 M(+1.4%) |
| Sep 2007 | - | $45.08 M(+35.1%) |
| Jun 2007 | - | $33.37 M(+1.2%) |
| Mar 2007 | - | $32.96 M(+43.3%) |
| Dec 2006 | $23.01 M(+899.0%) | $23.01 M(+734.6%) |
| Sep 2006 | - | $2.76 M(+13.7%) |
| Jun 2006 | - | $2.43 M(-9.9%) |
| Mar 2006 | - | $2.69 M(+16.9%) |
| Dec 2005 | $2.30 M(+45.8%) | $2.30 M(+27.2%) |
| Sep 2005 | - | $1.81 M(+5.6%) |
| Jun 2005 | - | $1.72 M(-11.0%) |
| Mar 2005 | - | $1.93 M(+22.1%) |
| Dec 2004 | $1.58 M(+477.7%) | $1.58 M(-20.7%) |
| Sep 2004 | - | $1.99 M(+53.9%) |
| Jun 2004 | - | $1.29 M(+67.3%) |
| Mar 2004 | - | $773.20 K(+182.8%) |
| Dec 2003 | $273.40 K(-55.2%) | $273.40 K(+5595.8%) |
| Sep 2003 | - | $4800.00(0.0%) |
| Jun 2003 | - | $4800.00(-66.7%) |
| Mar 2003 | - | $14.40 K(-97.6%) |
| Dec 2002 | $610.10 K(>+9900.0%) | $610.10 K(>+9900.0%) |
| Sep 2002 | - | $4600.00(+39.4%) |
| Jun 2002 | - | $3300.00(-35.3%) |
| Mar 2002 | - | $5100.00 |
| Dec 2001 | $3300.00 | - |
FAQ
- What is Halozyme Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual total liabilities year-on-year change?
- What is Halozyme Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly total liabilities year-on-year change?
What is Halozyme Therapeutics annual total liabilities?
The current annual total liabilities of HALO is $1.70 B
What is the all time high annual total liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual total liabilities is $1.70 B
What is Halozyme Therapeutics annual total liabilities year-on-year change?
Over the past year, HALO annual total liabilities has changed by +$50.19 M (+3.04%)
What is Halozyme Therapeutics quarterly total liabilities?
The current quarterly total liabilities of HALO is $1.70 B
What is the all time high quarterly total liabilities for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly total liabilities is $1.77 B
What is Halozyme Therapeutics quarterly total liabilities year-on-year change?
Over the past year, HALO quarterly total liabilities has changed by $0.00 (0.00%)